FindMyKOL
Clinical trialNCT06474507RecruitingInterventional

Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)

NCT06474507 is an interventional trial sponsored by Tongji Hospital. As of 18 Nov 2026, it is recruiting participants. It studies Bos taurus gallstone preparation in Acute Ischemic Stroke, Cerebral Small Vessel Diseases and 1 more condition. The registry lists an enrollment of 230 participants at 2 sites in 1 country. The registry lists a start date of 8 Aug 2024 and a primary completion date of 31 Jul 2029. One of its registered investigators has a FindMyKOL profile.

SponsorTongji Hospital →Enrollment230Acute Ischemic StrokeCerebral Small Vessel DiseasesIschemic Cerebrovascular Disease
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06474507
FieldValue
Registry IDNCT06474507
StatusRecruiting
Study typeInterventional trial
Lead sponsorTongji Hospital
Enrollment230
Registered sites2
Countries1
ConditionsAcute Ischemic Stroke, Cerebral Small Vessel Diseases and Ischemic Cerebrovascular Disease
DrugsBos taurus gallstone preparation
Start8 Aug 2024
Primary completion31 Jul 2029
Study completion31 Dec 2029
Last update posted20 Sept 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The most common cause of death for Chinese patients is ischemic cerebrovascular diseases(ICVD), particularly cerebral infarction. It places a heavy burden on people, families, and society as a whole and poses considerable risks of death and disability. The disease known as CSVD has a subtle beginning, is difficult to identify, and is frequently detected only after it progresses to the point of vascular cognitive dysfunction. The primary ischemia necrosis of brain nerve cells and the activation of inflammatory cells are their pathologic processes. According to historical Chinese medical documents, bezoar possesses properties that can help prevent seizures, treat strokes, enhance cognitive function and mental well-being, and stimulate alertness. Calculus Bovis Sativus (CBS) is the most authentic formulation of bezoar ingredients compared to other bezoar products. It has received approval from the China Food and Drug Administration for the essential treatment of comatose patients. CBS consists of three primary constituents: bilirubin, bile acids, and taurine. Scientific evidence has demonstrated that all of these components possess anti-inflammatory, antioxidant, and neuroprotective properties. The investigators' objective is to carry out an investigator-initiated clinical study to assess the efficacy of orally administered CBS in treating ischemic cerebrovascular diseases in humans.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China2 sites, 2 recruiting
  • Tongji Hospital Affiliated To Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei

    Chuan Qin, MDDaishi Tian, MDJun Xiao, MDKe Fang, MDKe Shang, MDLuo-qi Zhou, MDWei Wang, MD →
    Recruiting
  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei

    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bos taurus gallstone preparation
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06474507

Each answer restates registry values shown on this page.

What is NCT06474507?

NCT06474507 is an interventional trial sponsored by Tongji Hospital. It studies Bos taurus gallstone preparation in Acute Ischemic Stroke, Cerebral Small Vessel Diseases and 1 more condition.

Is NCT06474507 recruiting?

As of 18 Nov 2026, it is recruiting participants. 2 of its 2 sites list their own status as recruiting.

Who leads NCT06474507?

The registry names Wei Wang, MD (principal investigator, Tongji Hospital) as the overall official.

Where does NCT06474507 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: China.

Which drugs does NCT06474507 study?

The registered drug and biological interventions are Bos taurus gallstone preparation.

When is NCT06474507 expected to complete?

The registry lists a primary completion date of 31 Jul 2029 and a study completion date of 31 Dec 2029. The sponsor last updated the record on 20 Sept 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.